Pharma Pulse 3/14/24: Women’s Health Research Aims to Make Menopause Optional, FDA Accepts NDA & more

Reducing the Emotional and Logistical Burdens of Patient Participation

In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses what kinds of technologies can be developed to improve patient engagement while still maintaining data integrity.

Innovations in Women’s Health Research Aim to Make Menopause Optional

Menopause can have severe repercussions on female health which impact quality of life and health span, according to an expert of women’s health.

Varda Hopes New Research Draws More Drugmakers to Space Factories

The startup’s space technology is designed to capitalize on the benefits of microgravity for drug developers.

US FDA Has Accepted the NDA for Ensartinib

Xcovery Holdings, Inc., an oncology focused pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).

From Danielle Maxson on LinkedIn:

Thank you for writing this. As a medical translator, I've been concerned about using AI in any facet of my work. I appreciate your emphasis on the need for oversight by human experts.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs